EMERYVILLE, Calif., Jan. 6, 2025 /PRNewswire/ — Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced that the Company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. Warner Biddle, Chief Executive Officer of Kyverna, will present its 2025 strategic priorities and key… Continue reading Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference
Tag: Morgan
Waystar to Present at J.P. Morgan Healthcare Conference
LEHI, Utah and LOUISVILLE, Ky., Jan. 6, 2025 /PRNewswire/ — Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced that Chief Executive Officer Matt Hawkins will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. PT. Waystar will provide a live webcast… Continue reading Waystar to Present at J.P. Morgan Healthcare Conference
Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 6, 2025 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m. Pacific Time on Monday January 13, 2025 in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference. The live presentation will be webcast and may be accessed… Continue reading Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
LEEDS EQUITY CONTINUES GROWTH OF ITS SENIOR TEAM
NEW YORK, Jan. 6, 2025 /PRNewswire/ — Leeds Equity Partners, LLC (“Leeds Equity”), the New York-based private equity firm, today announced the promotion of Emily Bernstein to Principal. Leeds Equity was founded in 1993 and invests exclusively in the Knowledge Industries. “Having joined our team a year ago with significant prior private equity experience, Emily… Continue reading LEEDS EQUITY CONTINUES GROWTH OF ITS SENIOR TEAM
Smithfield Foods Files Registration Statement for Proposed Initial Public Offering
SMITHFIELD, Va., Jan. 6, 2025 /PRNewswire/ — Smithfield Foods, Inc. (the “Company”), an American food company and an industry leader in value-added packaged meats and fresh pork, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) to sell shares of its common… Continue reading Smithfield Foods Files Registration Statement for Proposed Initial Public Offering
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
AUSTIN, Texas, Jan. 6, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating in investor, industry and business development meetings at the 43rd Annual J.P.… Continue reading Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
Sling Therapeutics Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Mich., Jan. 6, 2025 /PRNewswire/ — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced that Raymond Douglas, M.D., Ph.D., Chief Scientific Officer of Sling, will present at the 43rd Annual J.P. Morgan Healthcare Conference being held… Continue reading Sling Therapeutics Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Haemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 6, 2025 /PRNewswire/ — Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 5:15 pm Pacific Time. The public may access Mr. Simon’s presentation live via audio webcast at: https://jpmorgan.metameetings.net/events/healthcare25/sessions/58190-haemonetics-corporation/webcast?gpu_only=true&kiosk=true The live… Continue reading Haemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO and SUZHOU, China, Jan. 5, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference.… Continue reading Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference
ENPH Class Action Lawsuit Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Enphase Energy, Inc. (ENPH) Investors that a Securities Fraud Class Action Lawsuit Has Been Filed
RADNOR, Pa., Jan. 5, 2025 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Enphase Energy, Inc. (NASDAQ: ENPH) (“Enphase” or the “Company”) on behalf of all persons and entities who purchased or otherwise acquired Enphase common stock… Continue reading ENPH Class Action Lawsuit Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Enphase Energy, Inc. (ENPH) Investors that a Securities Fraud Class Action Lawsuit Has Been Filed